What are the side effects of Vemurafenib?

The most common adverse events with Vemurafenib are cutaneous manifestations, including but not limited to nonspecific maculopapular rash, hyperkeratosis, and photosensitivity, particularly during radiation therapy. After the marketing of vemurafenib, there have been cases of progression of pre-existing chronic myelomonocytic leukemia and benign, malignant and unspecified tumors (including cysts and polyps) with NRAS mutations, Drug reactions with eosinophilia and systemic symptoms, neutropenia, pancreatitis, acute interstitial nephritis, acute tubular necrosis, Dupuytren's contracture, plantar fascial fibromatosis.

One of the most significant cutaneous adverse events with vemurafenib is skin cancer, including squamous cell carcinoma and keratoacanthoma in approximately 30% of cases, and less commonly, the development of new primary melanoma. This adverse reaction usually occurs within weeks of starting treatment and is managed medically with surgical resection without the need to discontinue the BRAF inhibitor. In addition, the development of secondary melanoma may occur during treatment due to paradoxical activation of the MAP kinase pathway, and clinical trials have shown that combining BRAF inhibitors with MEK inhibitors is associated with a reduced risk of skin tumors but more skin side effects.

Vemurafenib The original drug has been launched in China and has entered the scope of medical insurance. The price of 240mg*56 tablets per box may be around 7,000 yuan, which is very expensive. The Turkish version of Vemurafenib Original drug listed overseas, specifications240mg*56 tablets, may cost more than 2,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively cheap. There is currently no generic version of Vemurafenib on the market. For more drug information and specific prices, please consult a medical consultant.